Dr. McDermott on the Role of VEGF Targeted Therapy in RCC

David F. McDermott, MD
Published: Thursday, May 11, 2017



David F. McDermott, MD, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the role of VEGF-targeted therapy in renal cell carcinoma (RCC).

For most newly diagnosed patients, the standard of care is a VEGF-targeted agent, as clear cell kidney cancers are very VEGF driven, McDermott says.

Many patients end up developing resistance though—at least half within the first year—suggesting the need for the development of new therapies in this setting.
 


David F. McDermott, MD, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the role of VEGF-targeted therapy in renal cell carcinoma (RCC).

For most newly diagnosed patients, the standard of care is a VEGF-targeted agent, as clear cell kidney cancers are very VEGF driven, McDermott says.

Many patients end up developing resistance though—at least half within the first year—suggesting the need for the development of new therapies in this setting.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x